Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms
Male
0301 basic medicine
microglia
metabolism [Microglia]
metabolism [Apolipoproteins E]
Mice
03 medical and health sciences
Apolipoproteins E
Animals
ddc:610
tau
metabolism [Nerve Degeneration]
Mice, Knockout
genetics [Tauopathies]
myelin
LDLR
metabolism [Receptors, LDL]
Receptors, LDL
Tauopathies
Nerve Degeneration
genetics [Apolipoproteins E]
Microglia
metabolism [Tauopathies]
OPC
metabolism
ApoE
DOI:
10.1016/j.neuron.2021.05.034
Publication Date:
2021-06-21T14:30:39Z
AUTHORS (16)
ABSTRACT
APOE is the strongest genetic risk factor for late-onset Alzheimer's disease. ApoE exacerbates tau-associated neurodegeneration by driving microglial activation. However, how apoE regulates microglial activation and whether targeting apoE is therapeutically beneficial in tauopathy is unclear. Here, we show that overexpressing an apoE metabolic receptor, LDLR (low-density lipoprotein receptor), in P301S tauopathy mice markedly reduces brain apoE and ameliorates tau pathology and neurodegeneration. LDLR overexpression (OX) in microglia cell-autonomously downregulates microglial Apoe expression and is associated with suppressed microglial activation as in apoE-deficient microglia. ApoE deficiency and LDLR OX strongly drive microglial immunometabolism toward enhanced catabolism over anabolism, whereas LDLR-overexpressing microglia also uniquely upregulate specific ion channels and neurotransmitter receptors upon activation. ApoE-deficient and LDLR-overexpressing mice harbor enlarged pools of oligodendrocyte progenitor cells (OPCs) and show greater preservation of myelin integrity under neurodegenerative conditions. They also show less reactive astrocyte activation in the setting of tauopathy.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (50)
CITATIONS (91)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....